From outpatient migration to an evolving healthcare cost landscape, spine and orthopedic surgeons have discussed the trends they’re watching on the “Becker’s Spine and Orthopedic Podcast.” Editor’s ...

Anyone dealing with a painful injury or chronic orthopedic condition just wants to feel better and get back to their life.

Zydus Lifesciences is working to advance its position in the global pharmaceutical sector by increasing its focus on medical ...

India still relies largely on imported devices and implants, when it comes to MedTech. This offers us a great opportunity to ...

The Indian Pharmaceutical Alliance (IPA), representing major drug manufacturers like Cipla, Dr. Reddy's Laboratories, and Lupin, has urged the government to eliminate import duties on pharmaceutical ...

Mumbai: The Indian Pharmaceutical Alliance (IPA), which represents the country's largest drug makers such as Cipla, Dr Reddy's Laboratories and Lupin, has suggested to the government to bring down the ...

Cipla also maintained steady momentum, expanding by 6.9%, with notable contributions from respiratory and anti-infective segments. A key player in new brand sales was Dr. Reddy’s Laboratories, which ...

Cipla MD and CEO Umang Vohra said that ''derisking our top launches remains our top priority'' as the company focuses on resolving regulatory issues at various manufacturing plants. ''Our focus ...

Thirty three stocks in the Nifty50 basket closed lower, with Cipla, Hindalco, Dr Reddy's, ONGC, Reliance, JSW Steel and Tata Steel — falling around 2-5 per cent for the day — being the top laggards.

Also Read: Dr Reddy's to buy US generic product portfolio of Australia-based Mayne Pharma Of 20 stocks in Nifty Pharma, 14 ended in the red, while the remaining were in the green today at the market ...

About 1944 shares have advanced, 1285 shares declined, and 124 shares are unchanged. Tech Mahindra, Cipla, Dr Reddy’s Laboratories, UPL and Kotak Mahindra Bank were among the topgainers on the ...